TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in health system utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SIBO evaluation by lactulose breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CLE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SES-CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathology score for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Complete Spontaneous Bowel Movement (CSBM) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immediate effectiveness of outpatient respiratory physiotherapy treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With FLACC Pain Scores ≥7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BM uMRD CR 3 months after end of intensification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in denture stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in masticatory efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in patient's satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in oral health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in Peri-implant crestal alveolar bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Severity of Aspiration Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Series Completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Golimumab concentrations (peak/trough, AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walk distance (6 MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of FVIII neutralizing antibody
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of pro- and anti-inflammatory proteins in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with no adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional urinary sodium excretion (FENa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Borg Dyspnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetics of co-administration of pravastatin & cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Donor left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resolution of chronic maxillary sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGF/creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGE2/creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP/creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients requiring ventilatory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wound infection (including deep abscess)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Anti-Xa Levels Within Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responder patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of adverse pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived fear avoidance beliefs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight of abnormal (watery/liquid) stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change of transactional sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change of Forced sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Composite of Safety and Effectiveness
Endpoint domain: Adverse events/effects
Primary endpoint: Verbal fluency test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Eradication of MRSA carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to Completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline in full-field light sensitivity threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peer violence victimisation in the past 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peer violence perpetration in the past 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropathic pain sensory sign validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Corresponding symptoms of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COX-1 and COX-2 mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-1 and COX-2 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ECG QTc intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in post supplementation vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Technical success of the Viabahn BX stent graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events related to the Viabahn BX stent graft
Endpoint domain: Adverse events/effects
Primary endpoint: Percentual change of sVCAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change of Pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the composition of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in nutritional status of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in survival status after lung transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Birth injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Moderate/severe respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: NICU admission > 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average delta pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Objective Response (OR) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Post-baseline in ECOG Performance Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Treatment-related Non-serious Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of All Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Immunerelated AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Infusion-related Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life as measured by the EPIC Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical episodes of UVI
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects reporting adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Confirmed Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunologic memory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fMRI scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Cortex Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of 68Ga-DOTATOC PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of 68Ga-DOTATOC PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Count of Participants With Stable Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in International Knee Documentation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual analog pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft re-rupture rate
Endpoint domain: Mortality/survival
Primary endpoint: Homocysteine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cholesterol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve up to the last time point at which the concentration is above the lower limit of quantification [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The observed maximum serum drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary actin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum actin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fat free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Survived
Endpoint domain: Mortality/survival
Primary endpoint: media use time
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: discipline techniques used
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: firearm storage patterns
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: morphine sulphate consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life at two years post-surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Inflammatory and fibrotic components of esophageal stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants of Clinically Relevant Toxicities (CRT)
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year Disease Free Survival (DFS) Rate of Trastuzumab Emtansine (TDM-1)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of corticosteroid dose to ≤ 7.5 mg/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic improvement without ongoing SLE treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Renal response improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Weaning Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log change in HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: optimal dose-taking adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Within Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BCDVA (Letters Read)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successive suppressed viral load measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complications of HIV disease, including survival
Endpoint domain: Mortality/survival
Primary endpoint: Absolute number and percentage of CD4 and CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in speaking fundamental frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in formant frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in listeners perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in uric acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of the First Program Module
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: IKDC Subjective Knee Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 100 mm VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Other Anemia Therapy or Hb Trigger
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) of LOC-Paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of Weekly LOC-Paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in SGaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: plasma vitamin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pressure wave form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maturation of Arteriovenous Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline muscle strength after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline walking speed after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline endurance after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean hemodynamics response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Endothelin 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Tumor Necrosis Factor (TNF) alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospital length of stay in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Tolerance of oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of lower gastrointestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: symptomatic recurrent DVT or symptomatic fatal and non-fatal PE
Endpoint domain: Mortality/survival
Primary endpoint: deterioration in thrombotic burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels of the active ingredient in AHIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic iron content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of posttraumatic stress disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Investigator's Global Assessment (IGA) of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological test battery performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCSD Performance-Based Skills Assessment score
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Patient Emotional Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radicular Pain Visual Analogue Scale (VAS) Score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vomiting and nausea per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pro-inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-inflammatory mediators IL-1 receptor antagonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-inflammatory mediators IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Appearance of Surgical Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hip Range of Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of submucous tissue harvested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of Resection (Central Post-Resection Biopsies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of Resection (Peripheral Post-Resection Biopsies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: KOOS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kujala
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Balance Error Scoring System Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in University of Wisconsin Running Injury and Recovery Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Single Assessment Numerical Evaluation (SANE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelialization test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of self-reported pain on 100mm Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of functional status recorded with the Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Candida albicans colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Adverse Events According to NCI CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Total Dysmenorrhea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of visual analogue (VAS) scores of reflow, heartburn and other major symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rate of acid inhibitors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: The change of recurrence rate of main symptoms in Nonerosive Reflux Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes